Program
Diazepam
Also written as “diazepam nasal spray”, “NRL-1” and “Diazepam Nasal Spray [Valtoco]”.
Its studies are mostly in Epilepsy · Seizures · Drug Resistant Epilepsy, led by 4 companies.
Drug pageDiazepam: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Acorda Therapeutics | 40 open or running | phase 2since Aug 12, 2011 | Aug 12, 2011 | none ahead |
| Neurelisits history only | 30 open or running | phase 3since Mar 17, 2016 | Mar 17, 2016 | none ahead |
| Pfizerits history only | 10 open or running | phase 3since Apr 27, 2006 | Apr 27, 2006 | none ahead |
| UCBits history only | 10 open or running | phase 1since Jun 5, 2025 | Jun 5, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Acorda Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 12, 2011First study: phase 2 study in EpilepsyFirst studyNCT01417078 · 31 enrolled · United States
- Dec 9, 2014Phase 2 study in EpilepsyNCT02316847 · 126 enrolled · United States
- Jun 15, 2015Phase 2 study in Drug Resistant EpilepsyNCT02474407 · 78 enrolled · United States
- Jan 22, 2016Phase 1 study in HealthyNCT02663999 · 15 enrolled · United States
TargetBeta
“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule
Other programs on the same 16 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Midazolamrule | Eli Lilly | phase 4 | 97 |
| ciprofolrule | Haisco Pharmaceutical Group | phase 4 | 36 |
| Alprazolamrule | Viatris | phase 4 | 35 |
| brexanolonerule | Supernus Pharmaceuticals | phase 4 | 14 |
Studies
All 4 Acorda Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02663999Healthy · United States | 1 | Completed | Apr 2016 | 15 |
| NCT02474407Drug Resistant Epilepsy · United States | 2 | Terminated | May 2016 | 78 |
| NCT02316847Epilepsy · United States | 2 | Terminated | Jul 2016 | 126 |
| NCT01417078Epilepsy · United States | 2 | Completed | Feb 2013 | 31 |
How it is read
Names in the registry
- “diazepam nasal spray”, 3 entries
- “Diazepam”, 2 entries
- “NRL-1”, 2 entries
- “Diazepam Nasal Spray [Valtoco]”, 1 entry
- “Vanquix Auto-Injector (Diazepam Injection)”, 1 entry
Conditions, from the studies’ own filings
- Epilepsy, 4 studies
- Seizures, 2 studies
- Drug Resistant Epilepsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.